Ertapenem Anaerobic Coverage
Ertapenem provides excellent broad-spectrum anaerobic coverage, including robust activity against Bacteroides fragilis group and other clinically important anaerobes, making it appropriate for empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity. 1
FDA-Approved Anaerobic Spectrum
According to the FDA label, ertapenem has established clinical efficacy against the following anaerobic bacteria 1:
Key Bacteroides species:
- Bacteroides fragilis
- Bacteroides distasonis
- Bacteroides ovatus
- Bacteroides thetaiotaomicron
- Bacteroides uniformis
Other clinically significant anaerobes:
- Clostridium clostridioforme
- Eubacterium lentum
- Peptostreptococcus species
- Porphyromonas asaccharolytica
- Prevotella bivia
Additional anaerobes with in vitro susceptibility (clinical efficacy not established in controlled trials):
- Bacteroides vulgatus
- Clostridium perfringens
- Fusobacterium spp.
Guideline-Based Recommendations
The 2010 IDSA/SIS guidelines for complicated intra-abdominal infections specifically recommend ertapenem as single-agent therapy for mild-to-moderate community-acquired infections requiring anaerobic coverage 2. This recommendation carries an A-I evidence rating (strong recommendation, high-quality evidence).
The guideline explicitly states that anaerobic coverage should be provided for:
- Distal small bowel infections
- Appendiceal infections
- Colon-derived infections
- Proximal GI perforations with obstruction or paralytic ileus
In Vitro Activity Profile
Research data demonstrates ertapenem's potent anaerobic activity 3, 4, 5:
MIC₅₀ values:
- B. fragilis group: 0.25-0.5 mg/L
- Prevotella spp.: 0.06-0.25 mg/L
- Fusobacterium spp.: 0.06 mg/L
- Gram-positive anaerobic cocci: ≤0.03 mg/L
Susceptibility rates: 98-99% of anaerobes are inhibited at ≤4 mcg/mL 3, 4, 6, with resistance rates of only 2.1% overall 3. This activity is comparable to imipenem and meropenem 7, 5.
Important Caveats
Limited activity against specific anaerobes:
- Clostridium difficile: Only 10 of 14 strains susceptible 6
- Clostridium innocuum: Limited data, some resistance noted 6
- Rare B. fragilis group isolates (<1%) may show reduced susceptibility (MIC ≥8 mcg/mL) 4
Clinical considerations:
- Ertapenem lacks anti-pseudomonal activity, distinguishing it from imipenem/meropenem 2
- The guideline specifically recommends against using anti-pseudomonal carbapenems for mild-to-moderate community-acquired infections to reduce toxicity risk and resistance selection 2
- Time-kill studies show bactericidal activity at 2× MIC after 48 hours 5
Mechanism: Ertapenem's anaerobic activity results from cell wall synthesis inhibition via penicillin-binding protein binding, with stability against most beta-lactamases (though hydrolyzed by metallo-beta-lactamases) 1.